Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589914 · ClinicalTrials.gov registry record · Phase 3
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,221
- Enrollment target
NCT00589914 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 1,221 participants.
The verdict
NCT00589914, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,221 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
Interventions
- DRUG Paliperidone palmitate
- DRUG RISPERDAL CONSTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,221 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589914
The ClinicalTrials.gov registry entry for NCT00589914 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paliperidone palmitate is the first listed.
NCT00589914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00589914 about?
NCT00589914 is a clinical study titled "Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia". The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
What is the current status of trial NCT00589914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,221 participants. The study started on 2007-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00589914?
The interventions under investigation include: Paliperidone palmitate (DRUG), RISPERDAL CONSTA (DRUG).
Who is sponsoring clinical trial NCT00589914?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.